- Home
- BSM vs MRUS Comparison
BSM vs MRUS Comparison
Compare BSM & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSM
- MRUS
- Stock Information
- Founded
- BSM 1876
- MRUS 2003
- Country
- BSM United States
- MRUS Netherlands
- Employees
- BSM N/A
- MRUS N/A
- Industry
- BSM Oil & Gas Production
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- BSM Energy
- MRUS Health Care
- Exchange
- BSM Nasdaq
- MRUS Nasdaq
- Market Cap
- BSM 3.1B
- MRUS 2.7B
- IPO Year
- BSM 2015
- MRUS 2016
- Fundamental
- Price
- BSM $13.64
- MRUS $41.56
- Analyst Decision
- BSM Hold
- MRUS Strong Buy
- Analyst Count
- BSM 2
- MRUS 14
- Target Price
- BSM $14.00
- MRUS $87.00
- AVG Volume (30 Days)
- BSM 325.8K
- MRUS 779.4K
- Earning Date
- BSM 05-05-2025
- MRUS 05-07-2025
- Dividend Yield
- BSM 11.00%
- MRUS N/A
- EPS Growth
- BSM N/A
- MRUS N/A
- EPS
- BSM 0.92
- MRUS N/A
- Revenue
- BSM $422,061,000.00
- MRUS $54,732,000.00
- Revenue This Year
- BSM $13.21
- MRUS $37.38
- Revenue Next Year
- BSM $7.04
- MRUS $24.81
- P/E Ratio
- BSM $14.83
- MRUS N/A
- Revenue Growth
- BSM N/A
- MRUS 42.77
- 52 Week Low
- BSM $12.80
- MRUS $33.19
- 52 Week High
- BSM $16.48
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- BSM 39.95
- MRUS 48.05
- Support Level
- BSM $13.45
- MRUS $39.60
- Resistance Level
- BSM $14.08
- MRUS $44.22
- Average True Range (ATR)
- BSM 0.26
- MRUS 2.41
- MACD
- BSM -0.03
- MRUS -0.20
- Stochastic Oscillator
- BSM 16.03
- MRUS 43.13
About BSM Black Stone Minerals L.P. Common units representing limited partner interests
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.